


Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to \$20.3 billion. For more information, visit www.tevapharm.com.


2014 Performance

(USD m)




Stock Chart

(As of Feb 4, 2015)




Net Revenues

(USD m)




Net Income (non GAAP¹)

(USD m)




Earnings Per Share (non GAAP) ⁽¹⁾

(USD)




Dividends Per Share

(USD)



(1) See non GAAP reconciliation in our report for the fourth quarter of 2014



2014 Main Achievements



- Delivered ~600m in net cost reductions
- Significantly improved **cash flow from operations** (from \$3.2b to \$5.1b) and **free cash flow** (from 2.3b to 4.3b)
- Generics Profit^{**}: improved by 510bps in 2014 (from 16.8% in 2013 to 21.9%)
- Launched 19 Generic products in the US, 209 Europe, and 87 ROW delivering ~\$1b in 2014 revenue
- Copaxone 40 mg conversion rate at ~63%
- Successfully Launched 4 new Specialty products with 2014 revenues of ~200m


Revenues by markets and segments

FY 2014



Profit^{**} by segment


FY 2014



* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices

** Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

Pipeline (as of Feb 5, 2015)



- 12 products in Phase 3 through registration
- 8 products in Phase 2

